OakChart

GoodRx Holdings Inc

GDRXHealthcare·Health Information Services·USA·Small·NASD·Nov 11 • 11:59 AM ET

3.54+0.00 (0.05%)
2026-11-11 17:59 CET
Market cap
1,207.65 USD m
Revenue, TTM
785.23 USD m
Net income, TTM
16.25 USD m
Free cash flow, TTM
197.09 USD m
EPS diluted, TTM
0.05
P/E
75.19
Compare

Price

GDRX against its 20, 50 and 200-day averages
2050200miss
2.503.003.502.2M4.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GDRXclose 3.5420-day 3.5350-day 3.44200-day 2.863.5452w high

8.9% under the 52-week high of 3.89 on 11 Aug 2026. 52-week low 1.77 on 2 Mar 2026. Last 15 sessions, 14.1% high to low

Profile

GDRX
52-week range, 83% of the way up
1.773.89

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. It offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Employees697
IPOSep 23, 2020
Beta1.65
ATR, 14d0.15
Rel volume0.48
Short float4.06%
Insider own74.22%
Inst own16.23%

Snapshot

6 groups

Valuation

Index-
Market Cap1.21B
Enterprise Value1.45B
Income16.25M
Sales785.23M
Book/sh1.90
Cash/sh0.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees697
IPOSep 23, 2020

Ratios

P/E75.19
Forward P/E10.08
PEG1.73
P/S1.54
P/B1.86
P/C4.08
P/FCF6.13
EV/EBITDA7.93
EV/Sales1.85
Quick Ratio1.38
Current Ratio1.38
Debt/Eq0.83
LT Debt/Eq0.82
Option/ShortYes / Yes

Earnings

EPS (ttm)0.05
EPS next Y0.35
EPS next Q0.08
EPS this Y-13.33%
EPS next Y15.79%
EPS next 5Y5.83%
EPS past 3/5Y- -
Sales past 3/5Y1.30% 7.67%
EPS Y/Y TTM-48.77%
Sales Y/Y TTM-1.83%
EPS Q/Q-31.94%
Sales Q/Q-1.31%
EarningsAug 05 AMC
EPS/Sales Surpr.0.38% 3.72%

Ownership

Insider Own74.22%
Insider Trans-1.08%
Inst Own16.23%
Inst Trans0.34%
ROA0.89%
ROE2.52%
ROIC1.38%
Gross Margin79.54%
Oper. Margin12.00%
Profit Margin2.07%
SMA200.45%
SMA502.94%
SMA20023.85%
Trades-

Technical

Shs Outstand106.16M
Shs Float87.95M
Short Float4.06%
Short Ratio3.01
Short Interest3.57M
52W High3.89 -8.96%
52W Low1.77 100.09%
Volatility6.13% 4.23%
ATR (14)0.15
RSI (14)51.92
Beta1.65
Rel Volume0.48
Avg Volume1.19M
Volume235,202

Performance

Perf Week-4.80%
Perf Month2.66%
Perf Quarter-4.80%
Perf Half Y35.69%
Perf YTD30.69%
Perf Year16.88%
Perf 3Y-26.06%
Perf 5Y-91.10%
Perf 10Y-
Recom2.73
Target Price3.95
Prev Close3.54
Price3.54
Change %0.05%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Feb 27, 2026DowngradeJJP MorganOverweight → Neutral
Jan 22, 2026DowngradeJJefferiesBuy → Hold$2.75-22.4%
Dec 09, 2025InitiatedBBarclaysUnderweight$3-15.3%
Aug 11, 2025DowngradeRRaymond JamesStrong Buy → Outperform
Dec 04, 2024InitiatedMMizuhoNeutral$5+41.2%
Aug 09, 2024UpgradeRRaymond JamesOutperform → Strong Buy$10+182.4%
May 23, 2024UpgradeRRBC Capital MktsSector Perform → Outperform$8 → $10+182.4%
May 16, 2024UpgradeRRaymond JamesMkt Perform → Outperform$10+182.4%
Apr 10, 2024UpgradeKKeyBanc Capital MarketsSector Weight → Overweight$9+154.1%
Mar 25, 2024UpgradeWWells FargoEqual Weight → Overweight$7.50 → $10+182.4%

Peers

Mkt cap
TickerCompanyMkt cap
OPRXOptimizeRx Corp178.19M
DOCSDoximity Inc5.83B
PHRPhreesia Inc782.89M
HIMSHims & Hers Health Inc4.71B
TDOCTeladoc Health Inc1.63B
LFMDLifeMD Inc80.74M
HQYHealthequity Inc8.45B
AMWLAmerican Well Corp211.41M
CVSCVS Health Corp112.53B
CICigna Group78.00B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 26 '26Sale3.501,296,1774,541,9170Aug 26 09:20 PM
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 24 '26Sale3.46143,594497,122706,649Aug 26 09:20 PM
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 25 '26Sale3.44127,273438,443643,466Aug 26 09:20 PM
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 19 '26Sale3.53471,9751,666,0251,127,436Aug 21 09:38 PM
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 20 '26Sale3.52447,2591,574,575913,592Aug 21 09:38 PM
FRANCISCO PARTNERS IV, L.P.10% OwnerAug 21 '26Sale3.50274,717960,630777,213Aug 21 09:38 PM
Francisco Partners GP IV, L.P.10% OwnerAug 19 '26Proposed Sale3.722,760,99510,270,901Aug 19 02:21 PM
IAN THORNTON CLARKDirectorMay 13 '26Proposed Sale2.5943,100111,620May 13 05:00 PM
REY-GIRAUD AGNESDirectorMar 12 '26Option Exercise0.47192,18590,327277,633Mar 13 07:22 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
DFSVUS Small Cap Value Portfolio ETF Class Shares-
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
SFLOVictoryShares Small Cap Free Cash Flow ETFAUM: 889.00M
DFASU.S. Small Cap Portfolio-ETF Class Shares-
DFACU.S. Core Equity 2 Portfolio-ETF Class Shares-

News

latest 14 of 206
  • GoodRx stock rises on Google Cloud healthcare AI partnership (Investing.com)
  • GoodRx Brings Prescription Pricing Intelligence to Google Cloud's Gemini for Healthcare (Business Wire)
  • GoodRx Launches Employer Direct Weight Loss Offering (Business Wire)
  • From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household (Business Wire)
  • GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call (Business Wire)
  • Loading…
  • GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs (Business Wire)
  • Trump Announces Discount Drug Pricing Expansion With Mark Cuban (Bloomberg)
  • GoodRx Reports First Quarter 2026 Results (Business Wire) +10.51%
  • GoodRx Expands Offerings to Now Include Ozempic Pill for Type 2 Diabetes Patients (Business Wire) +8.05%
  • GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call (Business Wire)
  • GoodRx Now Offers Access to Wegovy HD at $399 Per Month Self-Pay Price (Business Wire)
  • GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo, and Zepbound KwikPen with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide (Business Wire)
  • GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications (Business Wire) -6.25%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-050.0800.0800.020200.41193.2312
2026Q12026-05-060.0700.0720.003194.01185.412
2025Q42026-02-250.0900.0920.016194.79193.2712
2025Q32025-11-040.0800.0900.003196.03194.5411
2025Q22025-08-060.0900.0990.036203.07205.911
2025Q12025-05-070.0900.0950.029202.97202.2213
2024Q42025-02-270.0900.0910.018198.58199.7615
2024Q32024-11-070.0800.0870.010195.25195.6613
2024Q22024-08-080.0800.0870.017200.61200.4714
2024Q12024-05-090.0800.072-0.003197.88196.1115
2023Q42024-02-290.0800.068-0.064196.64194.317
2023Q32023-11-090.0600.058-0.093179.96188.5215
2023Q22023-08-090.0700.0610.142189.68186.8416
2023Q12023-05-100.0700.056-0.008183.99182.0918
2022Q42023-02-280.0700.046-0.005184.11178.518
2022Q32022-11-080.0700.042-0.101187.32185.0416

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY0.4470.359-0.750550.7545.1
2021FY0.3400.348-0.063745.42749.25
2022FY0.3000.278-0.080766.55760.83
2023FY0.2800.276-0.022750.27752.87
2024FY0.3400.3430.042792.32793.57
2025FY0.3500.3600.090796.85795.07
2026FY-0.303--799.58
2027FY-0.351--836.22
2028FY-0.415--893.16
2029FY-0.580--957.42

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-261201202.07199.1205.41
2026Q3S2026-10-231221202.07199.1205.41
2026Q3S2026-10-211221202.07199.1205.41
2026Q3S2026-10-201231202.07199.1205.41
2026Q3S2026-10-1612111202.07199.1205.41
2026Q3S2026-10-1212111202.07199.1205.41
2026Q3S2026-10-0912111202.07199.1205.41
2026Q3S2026-10-0612111201.93199.1205.41
2026Q3S2026-09-2512120202.12199.1205.41
2026Q3S2026-08-1313130202.44199.1206.37
2026Q3S2026-08-1213130202.46199.1206.37
2026Q3S2026-08-1013110201.06192206.37
2026Q3S2026-08-0713100199.93191.65205.41
2026Q3S2026-08-061390199.37191.65204.9

Estimate history

EPS, annual0.0230.0370.111-0.75-0.063-0.08-0.0220.0420.0850.0471
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0170.010.0180.0290.0360.0030.0160.0030.025
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual157.24249.522388.224550.7745.424766.554750.265792.324796.853785.23
Period201720182019202020212022202320242025TTM
Sales, quarterly200.61195.251198.583202.97203.07196.028194.785194.006200.411
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual385.385385.385385.385391.66400.562397.025394.087382.815341.052340.128
Period201720182019202020212022202320242025MRQ
Shares, quarterly378.607380.796382.815360.813352.771341.173341.052337.577340.128
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue785.23796.85792.32750.26766.55745.42550.70388.22249.52
Cost of Goods Sold Incl. D&A160.66142.72117.75170.09118.8181.2548.0227.5915.84
Gross Profit624.57654.13674.57580.17647.74664.17502.68360.63233.68
Selling, General and Administrative Excl. Other530.32547.16585.28528.80610.58636.47770.08218.79156.41
Research and Development116.77117.27123.75133.44138.88125.8661.8229.3043.89
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income94.25106.9789.2951.3837.1627.70-267.39141.8577.27
Interest Expense40.8142.6052.9256.7334.2423.6427.9149.5722.19
Unusual Expense19.3119.4825.5277.0346.8314.308.337.052.87
Net Income Before Taxes41.4056.5431.46-55.57-23.23-10.18-303.4582.9852.35
Income Taxes25.1526.1015.07-46.709.6015.08-9.8316.938.55
Consolidated Net Income16.2530.4416.39-8.87-32.83-25.25-293.6242.4426.78
Net Income From Continuing Operations16.2530.4416.39-8.87-32.83-25.25-293.6242.4426.78
Net Income16.2530.4416.39-8.87-32.83-25.25-293.6242.4413.79
EPS (Recurring)0.090.120.090.11-0.00-0.04-0.730.120.04
EPS (Basic, Before Extraordinaries)0.050.090.04-0.02-0.08-0.06-0.750.110.04
EPS (Diluted)0.050.090.04-0.02-0.08-0.06-0.750.110.04
EBITDA182.89192.19158.83163.1594.6965.34-244.48157.5787.07
Non-Operating Income (Expense)7.2611.6520.6126.8120.680.060.18-2.250.15
Other After Tax Adjustments0.000.000.000.000.000.000.00-23.61-17.01
Stock Option Compensation Expense64.7760.5378.2382.8194.98117.14290.022.741.39
Price To Earnings Ratio75.1675.16-186.11---799.43-
Price To Sales Ratio1.281.212.303.662.5117.5628.69--
Gross Margin79.5482.0985.1477.3384.5089.1091.2892.8993.65
Operating Margin12.0013.4211.276.854.853.72-48.5536.5430.97
Net Margin2.073.822.07-1.18-4.28-3.39-53.3210.935.53
Shares Outstanding340.13341.05382.81394.09397.02400.56391.66385.38385.38
Market Capitalization1,207.651,207.651,772.312,721.081,846.2513,035.4315,743.9816,505.03-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue200.41194.01194.78196.03203.07202.97198.58195.25
Cost of Goods Sold Incl. D&A43.2741.9540.6034.8533.0834.2831.2629.22
Gross Profit157.14152.06154.19161.18169.99168.69167.32166.03
Selling, General and Administrative Excl. Other132.66132.51130.38134.76142.28139.66140.54145.56
Research and Development26.7130.1828.8731.0129.9331.1430.5830.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income24.4819.5523.8026.4227.7129.0326.7920.47
Interest Expense9.819.7710.4010.8310.7310.6411.3612.36
Unusual Expense0.855.541.1211.800.905.658.612.14
Net Income Before Taxes15.475.6414.196.1019.5816.6711.418.11
Income Taxes6.934.478.774.986.735.624.674.15
Consolidated Net Income8.541.175.421.1212.8411.056.743.96
Net Income From Continuing Operations8.541.175.421.1212.8411.056.743.96
Net Income8.541.175.421.1212.8411.056.743.96
EPS (Recurring)0.030.010.020.030.040.040.030.01
EPS (Basic, Before Extraordinaries)0.030.000.020.000.040.030.020.01
EPS (Diluted)0.020.000.020.000.040.030.020.01
EBITDA46.7541.3446.9547.8547.4449.9545.8838.01
Non-Operating Income (Expense)1.641.401.912.313.503.934.592.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.1116.0917.7717.8016.9215.1516.5620.84
Price To Earnings Ratio75.1623.2831.5545.5867.03103.52--
Price To Sales Ratio1.280.851.161.842.222.102.253.41
Gross Margin78.4178.3879.1682.2283.7183.1184.2685.04
Operating Margin12.2110.0812.2213.4813.6514.3013.4910.48
Net Margin4.260.602.790.576.325.453.392.03
Shares Outstanding340.13337.58341.05341.17352.77360.81382.81380.80
Market Capitalization1,207.65671.45919.861,469.711,778.701,691.721,772.312,633.40

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments261.82448.35672.30757.16941.11971.5926.0534.6017.54
Short Term Receivables254.87160.83160.04121.67126.4197.2948.1333.360.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets126.4150.0840.4540.8621.3117.4812.405.110.00
Total Current Assets643.10659.25872.79919.691,088.831,086.3786.5873.070.00
Net Property, Plant & Equipment41.0840.4645.8655.7349.3250.7734.170.990.00
Total Investments and Advances15.0015.0015.0019.000.000.000.000.000.00
Intangible Assets633.67587.65567.11602.05463.47317.83262.67238.690.00
Deferred Tax Assets69.2877.1865.2723.2036.2737.5917.440.87-
Other Assets14.108.5222.778.166.012.021.161.180.00
Total Assets1,416.231,388.071,588.801,627.841,643.891,494.59402.03314.79286.87
Short Term Debt Incl. Current Port. of LT Debt9.7510.6414.9611.1012.8811.579.975.430.00
Accounts Payable19.4114.1436.2717.7017.5010.297.857.200.00
Income Tax Payable0.001.46---0.001.350.00-
Other Current Liabilities216.8497.6771.3347.5250.7337.6914.213.990.00
Total Current Liabilities246.00123.90122.5676.3281.1159.5533.3716.620.00
Long Term Debt533.05532.75696.11705.93689.45693.36701.02716.81136.01
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities12.17--23.5036.5124.4815.233.46-
Other Liabilities8.746.758.187.265.145.852.973.330.00
Total Liabilities799.97663.41826.84813.01812.22783.23752.60740.21136.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00737.01737.01166.78
Common Equity616.26724.66761.96814.83831.68711.36-1,087.58-1,162.43-31.75
Total Shareholders Equity616.26724.66761.96814.83831.68711.36-350.57-425.42135.02
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity616.26724.66761.96814.83831.68711.36-350.57-425.42135.02
Total Liabilities & Stockholders Equity1,416.231,388.071,588.801,627.841,643.891,494.59402.03314.79271.03
Book Value Per Share1.811.891.932.052.081.82-2.82-3.02-0.08
Tangible Book Value Per Share-0.050.360.490.540.921.00-3.50-3.64-0.08
Full-Time Employees697738694954777478---
Price to Book Ratio1.862.543.032.3415.7422.2121.76--
Return on Assets2.171.10-0.55-2.01-1.61-30.9611.848.903.04
Return on Equity4.542.21-1.12-3.99-3.27-162.77--12.36
Return on Invested Capital2.651.30-0.61-2.16-1.66-20.9012.119.193.26
Quick Ratio2.615.327.1212.0513.4218.242.594.40-
Current Ratio2.615.327.1212.0513.4218.242.594.40-

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income16.2530.4416.39-8.87-32.83-25.25-293.6266.0543.79
Depreciation88.6485.2269.54111.7757.5337.6422.9115.729.81
Other Funds (Non Cash)77.2588.62107.78122.89142.87165.34445.4312.015.86
Funds from Operations211.98224.35181.80160.23167.07190.57163.8088.1057.02
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-10.40-56.442.09-21.94-20.29-11.80-32.46-4.82-11.77
Cash from Operating Activities201.58167.90183.89138.29146.78178.78131.3483.2945.25
Capital Expenditures-69.88-74.02-70.35-55.77-55.21-34.46-35.82-5.75-3.46
Net Assets From Acquisitions-13.44-43.440.000.00-171.86-144.28-55.79-31.310.00
Sale of Fixed Assets and Businesses0.000.000.000.0016.580.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-2.50-2.500.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-85.82-119.96-70.35-55.77-210.50-178.73-91.62-37.05-3.46
Cash Dividends Paid0.000.000.000.000.000.000.000.00-1,346.36
Change in Capital Stock-85.34-216.31-139.80-98.03-92.5635.02992.874.67740.36
Repurchase of Common Pref Stock-85.00-216.37-158.84-103.97-101.720.000.000.000.00
Sale of Common Pref Stock-0.340.0619.055.949.1635.02992.874.67740.36
Proceedsfrom Stock Options-0.490.000.000.000.000.00986.861.62737.01
Issuance or Reduction of Debt, Net-5.00-5.00-169.68-5.27-7.03-7.03-8.34-59.45581.26
Change in Long Term Debt-5.00-5.00-169.68-5.27-7.03-7.03-8.34-59.45581.26
Issuance of Long Term Debt0.000.00469.360.000.000.0026.69152.40876.20
Reduction of Long Term Debt-5.00-5.00-639.04-5.27-7.03-7.03-35.03-211.84-294.94
Net Financing Active Other Cash Flow-10.62-13.16-28.02-64.09-20.64-58.52-78.710.000.00
Other Financing Activities Uses-11.93-14.47-29.78-65.48-20.64-58.52-78.710.000.00
Cash from Financing Activities-100.96-234.47-337.50-167.40-120.23-30.53905.82-54.78-24.73
Net Change in Cash14.79-186.53-223.95-84.87-183.94-30.48945.54-8.5517.06
Free Cash Flow197.09164.38182.65137.25142.81174.21110.7981.8644.45
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Price to Free Cash Flow5.095.899.9820.0313.4775.14142.61--
Deferred Taxes & Investment Tax Credit-20.07-11.91-65.56-0.5012.85-10.91-5.67-2.43

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments296.11235.71261.82273.53281.32300.98
Short Term Receivables194.04244.62254.87216.91202.31172.02
Inventories0.000.000.000.000.000.00
Other Current Assets1,109.17786.14126.4175.0766.9967.21
Total Current Assets1,599.331,266.47643.10565.51550.61540.21
Net Property, Plant & Equipment39.1440.4941.0840.9741.4234.41
Total Investments and Advances15.0015.0015.0015.0015.0015.00
Intangible Assets628.88631.69633.67626.61625.57620.65
Deferred Tax Assets47.3453.0469.2869.0977.1877.18
Other Assets13.2414.5614.108.328.917.82
Total Assets2,342.932,021.251,416.231,325.511,318.711,295.27
Short Term Debt Incl. Current Port. of LT Debt10.369.989.759.769.8210.56
Accounts Payable8.9114.5319.4128.7325.4115.26
Income Tax Payable--0.007.6811.876.76
Other Current Liabilities1,138.61834.70216.84135.6983.8070.81
Total Current Liabilities1,157.87859.20246.00181.86130.91103.38
Long Term Debt528.59531.38533.05535.37537.72530.63
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--12.17---
Other Liabilities8.878.698.747.567.056.91
Total Liabilities1,695.331,399.27799.97724.79675.67640.92
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity647.60621.99616.26600.71643.03654.35
Total Shareholders Equity647.60621.99616.26600.71643.03654.35
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity647.60621.99616.26600.71643.03654.35
Total Liabilities & Stockholders Equity2,342.932,021.251,416.231,325.511,318.711,295.27
Book Value Per Share1.901.841.811.761.821.81
Tangible Book Value Per Share0.06-0.03-0.05-0.080.050.09
Full-Time Employees--697---
Price to Book Ratio1.861.081.542.322.752.33
Return on Assets0.891.242.172.372.482.07
Return on Equity2.523.224.544.905.274.43
Return on Invested Capital0.730.100.470.101.090.93
Quick Ratio1.381.472.613.114.215.23
Current Ratio1.381.472.613.114.215.23

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income8.541.175.421.1212.8411.05
Depreciation22.2721.7923.1521.4319.7320.91
Other Funds (Non Cash)18.3218.6920.6519.5823.0025.39
Funds from Operations54.8345.7261.2050.2255.5857.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital26.00-33.89-28.3225.80-6.00-47.94
Cash from Operating Activities80.8311.8432.8976.0249.589.41
Capital Expenditures-14.41-21.64-15.83-18.00-18.32-21.88
Net Assets From Acquisitions0.000.00-13.440.000.00-30.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-2.500.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-14.41-21.64-31.77-18.00-18.32-51.88
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.58-12.47-10.29-61.00-45.13-99.89
Repurchase of Common Pref Stock-1.95-12.57-9.43-61.05-45.99-99.90
Sale of Common Pref Stock0.370.10-0.860.060.860.00
Proceedsfrom Stock Options0.370.00-0.860.000.860.00
Issuance or Reduction of Debt, Net-1.25-1.25-1.25-1.25-1.25-1.25
Change in Long Term Debt-1.25-1.25-1.25-1.25-1.25-1.25
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-1.25-1.25-1.25-1.25-1.25-1.25
Net Financing Active Other Cash Flow-3.19-2.58-1.29-3.57-4.55-3.76
Other Financing Activities Uses-3.19-2.58-2.60-3.57-4.55-3.76
Cash from Financing Activities-6.02-16.30-12.83-65.81-50.93-104.90
Net Change in Cash60.40-26.11-11.71-7.79-19.66-147.37
Free Cash Flow80.4710.7031.6574.2849.199.27
Price to Free Cash Flow5.094.045.628.309.3911.18

Revenue breakdown

Other2024: 21.00M 2025: 17.69M
Pharma Direct2024: 107.24M 2025: 151.38M
Prescription Transactions2024: 577.55M 2025: 544.00M
Subscription2024: 86.54M 2025: 83.79M
United States2024: 792.32M 2025: 796.85M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.06%3.6M88.0M1.29M
2026-10-154.18%3.7M88.0M1.28M
2026-09-304.71%4.2M88.3M1.30M
2026-09-155.36%4.7M88.3M1.37M
2026-08-314.93%4.4M88.3M1.42M
2026-08-145.80%5.1M87.8M1.41M
2026-07-316.70%5.9M87.4M1.44M
2026-07-157.56%6.5M85.4M1.47M
2026-06-307.83%6.7M85.6M1.52M
2026-06-158.75%7.5M85.6M1.60M
2026-05-298.31%7.2M86.8M2.04M
2026-05-1512.54%10.9M86.9M2.35M
2026-04-308.52%7.6M89.4M2.72M
2026-04-159.32%8.3M89.3M2.96M
2026-03-319.73%8.7M89.3M3.08M
2026-03-1310.32%9.2M89.3M3.20M
2026-02-2712.25%10.9M89.3M2.78M
2026-02-1311.97%10.3M86.5M2.50M
2026-01-3012.36%10.8M87.5M2.36M
2026-01-1511.21%9.7M86.4M2.40M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.701.501.054.92615.000.000.869-0.0150.001
call5.000.000.050.021.6932752.000.121-0.0100.001
call7.500.000.050.002.9440.000.000.080-0.0130.001
put2.500.000.100.042.3241.000.00-0.131-0.0150.001
put5.001.101.901.513.7740.000.00-0.880-0.0100.001
put7.503.404.400.005.4620.000.00-0.920-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10NT 10-Q2026-09-30SEC
2026-11-10SCHEDULE 13GSEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-08SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-028-KCurrent report2026-10-27SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-08-26SCHEDULE 13D/ASEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-24SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-058-KCurrent report2026-07-31SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-06-188-KCurrent report2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08009.68M6
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Francisco Partners Management, LP17.74%
LSV ASSET MANAGEMENT1.72%
AMERIPRISE FINANCIAL INC1.40%
VANGUARD CAPITAL MANAGEMENT LLC1.21%
Silver Lake Group, L.L.C.1.04%
DIMENSIONAL FUND ADVISORS LP0.99%
RENAISSANCE TECHNOLOGIES LLC0.96%
VANGUARD PORTFOLIO MANAGEMENT LLC0.95%
Petrus Trust Company, LTA0.91%
AQR CAPITAL MANAGEMENT LLC0.69%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.86%
VANGUARD STRATEGIC EQUITY FUND0.37%
VANGUARD EXTENDED MARKET INDEX FUND0.31%
VANGUARD SMALL-CAP INDEX FUND0.30%
Pacer US Small Cap Cash Cows 100 ETF0.22%
VANGUARD SMALL-CAP VALUE INDEX FUND0.19%
U.S. SMALL CAP VALUE PORTFOLIO0.17%
Fidelity Extended Market Index Fund0.14%
Schwab U.S. Small-Cap ETF0.13%
Dimensional US Small Cap Value ETF0.12%

OakChart. GDRX. Cached 15 minutes.